Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • All of DSpace
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Kissi, Freda Dansoah"

Now showing 1 - 3 of 3
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Item
    Method Development for the Quantification of Piperaquine Phosphate and Dihydroartemisinin in Combination Tablets
    (August 2010) Kissi, Freda Dansoah
    This research developed a spectrometric method of analyzing Piperaquine phosphate and Dihydroartemisinin in combination tablets. Piperaquine phosphate in the tablets was analyzed by extracting with 0.001M HCl solution and taking its absorbance at 349nm. The LOD was 5.56 x 10 -5 %w/v and the LOQ was 1.68 x 10 -4 %w/v. HPLC conditions were ODS column with a mobile phase of acetonitrile and water with 0.1%v/v Trifluoroacetic acid (TFA), (40:60) at a flow rate of 1.0ml/min at a wavelength of 349nm and an injection volume of 20μl. The retention time was 3.2 minutes. The LOD was 4.9 x 10 -5 %w/v and the LOQ was 1.48 x 10 -4 %w/v. Dihydroartemisinin in the tablets was analysed by sonicating the tablet powder in diethyl ether for some time, filtering and evaporating the diethyl ether off. The residue was dissolved in methanol and reacted with conc HCl for 30 minutes at 30OC and the absorbance taken at 254nm. The LOD was 1.09 x 10 -4 %w/v and the LOQ was 3.31 x 10 -3 %w/v. HPLC conditions were ODS column with a mobile phase of acetonitrile and water with 0.1%v/v TFA (90:10) at a flow rate of 1.0ml/min at a wavelength of 220nm and an injection volume of 20μl.The retention time was 3.8 minutes. The LOD was 0.013 %w/v and the LOQ was 0.040 %w/v.
  • Loading...
    Thumbnail Image
    Item
    Method Development for the Quantification of Piperaquine Phosphate and Dihydroartemisinin in Combination Tablets
    (2010-07-15) Kissi, Freda Dansoah
    This research developed a spectrometric method of analyzing Piperaquine phosphate and Dihydroartemisinin in combination tablets. Piperaquine phosphate in the tablets was analyzed by extracting with 0.001M HCl solution and taking its absorbance at 349nm. The LOD was 5.56 x 10 -5 %w/v and the LOQ was 1.68 x 10 -4 %w/v. HPLC conditions were ODS column with a mobile phase of acetonitrile and water with 0.1%v/v Trifluoroacetic acid (TFA), (40:60) at a flow rate of 1.0ml/min at a wavelength of 349nm and an injection volume of 20μl. The retention time was 3.2 minutes. The LOD was 4.9 x 10 -5 %w/v and the LOQ was 1.48 x 10 -4 %w/v. Dihydroartemisinin in the tablets was analysed by sonicating the tablet powder in diethyl ether for some time, filtering and evaporating the diethyl ether off. The residue was dissolved in methanol and reacted with conc HCl for 30 minutes at 30OC and the absorbance taken at 254nm. The LOD was 1.09 x 10 -4 %w/v and the LOQ was 3.31 x 10 -3 %w/v. HPLC conditions were ODS column with a mobile phase of acetonitrile and water with 0.1%v/v TFA (90:10) at a flow rate of 1.0ml/min at a wavelength of 220nm and an injection volume of 20μl.The retention time was 3.8 minutes. The LOD was 0.013 %w/v and the LOQ was 0.040 %w/v.
  • Loading...
    Thumbnail Image
    Item
    Method Development for the Quantification of Piperaquine Phosphate and Dihydroartemisinin in Combination Tablets
    (2010-07-14) Kissi, Freda Dansoah
    This research developed a spectrometric method of analyzing Piperaquine phosphate and Dihydroartemisinin in combination tablets. Piperaquine phosphate in the tablets was analyzed by extracting with 0.001M HCl solution and taking its absorbance at 349nm. The LOD was 5.56 x 10 -5 %w/v and the LOQ was 1.68 x 10 -4 %w/v. HPLC conditions were ODS column with a mobile phase of acetonitrile and water with 0.1%v/v Trifluoroacetic acid (TFA), (40:60) at a flow rate of 1.0ml/min at a wavelength of 349nm and an injection volume of 20μl. The retention time was 3.2 minutes. The LOD was 4.9 x 10 -5 %w/v and the LOQ was 1.48 x 10 -4 %w/v. Dihydroartemisinin in the tablets was analysed by sonicating the tablet powder in diethyl ether for some time, filtering and evaporating the diethyl ether off. The residue was dissolved in methanol and reacted with conc HCl for 30 minutes at 30OC and the absorbance taken at 254nm. The LOD was 1.09 x 10 -4 %w/v and the LOQ was 3.31 x 10 -3 %w/v. HPLC conditions were ODS column with a mobile phase of acetonitrile and water with 0.1%v/v TFA (90:10) at a flow rate of 1.0ml/min at a wavelength of 220nm and an injection volume of 20μl.The retention time was 3.8 minutes. The LOD was 0.013 %w/v and the LOQ was 0.040 %w/v.

Kwame Nkrumah University of Science and Technology copyright © 2002-2025